Investor Presentaiton

Identifiable and Achievable Cost Synergies and Meaningful Additional Upside + RCM and Branch Support + Direct and Indirect Spend Potential Cost Synergies + Branch Consolidation + Technology + G&A Additional Revenue Synergy Opportunities + PAP 90-day compliance + PAP resupply compliance + Payment collections efficiency + Cross-selling respiratory medication and diabetes products ++ adapthealth ~$25 million of cost synergies expected to be realized in 2021 $50 million estimated pre-tax run-rate annual synergies Additional revenue synergies not included in forecast 13

View entire presentation